Ethyl 3-aminopent-4-enoate → Ethyl 3-[[4-[[4-(aminoiminomethyl)naphthyl](phenylmethyl)-amino]-1,4-dioxobutyl]amino]-4-pentenoate

HRID 1741194

반응식

HRID 1741194 반응식
Cl.[NH2:2][N:3]=[CH:4][C:5]1[C:14]2[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=2)[C:8]([NH:15][C:16](=[O:22])[CH2:17][CH2:18][C:19]([OH:21])=O)=[CH:7][CH:6]=1.[NH2:23][CH:24]([CH:31]=[CH2:32])[CH2:25][C:26]([O:28][CH2:29][CH3:30])=[O:27]>>[NH2:2][N:3]=[CH:4][C:5]1[C:14]2[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=2)[C:8]([N:15]([CH2:4][C:5]2[CH:14]=[CH:9][CH:8]=[CH:7][CH:6]=2)[C:16](=[O:22])[CH2:17][CH2:18][C:19]([NH:23][CH:24]([CH:31]=[CH2:32])[CH2:25][C:26]([O:28][CH2:29][CH3:30])=[O:27])=[O:21])=[CH:7][CH:6]=1

참가 물질

3

실험 절차

The title compound was prepared in the manner of Example 1 substituting 4-[[4-(aminoiminomethyl)naphthyl]amino]-4-oxobutanoic acid hydrochloride for 4-[[4-(aminoiminomethyl)-3-phenyl]amino]-4-oxobutanoic acid hydrochloride and using ethyl 3-amino-4-pentenoate. The product was purified by reverse phase HPLC using the conditions of Example 1 to afford the title compound. The product was verified by 13C NMR (CD3OD) δ 13.2, 30.5, 31.3, 39.0, 48.5, 60.4, 114.6, 120.3, 123.1, 123.9, 124.8, 126.6, 127.0, 128.0, 128.1, 130.3, 136.8, 137.4, 167.6, 171.0, 172.6, 173.0; Chemical Ionization Mass Spectrometry (MH+)=411

후처리

  1. customThe product was purified by reverse phase HPLC

출처 및 근거

ORD 기록
ord-84a66bfec61a4af1af42d4549bbd5ccc
출처 데이터셋
uspto-grants-1999_10
특허 번호
US05973003

연결된 노트

불러오는 중…